3.00
0.00
(0.00%)
May 17 - Close
CPH
real-time data -
Disclaimer
Currency in DKK
| Range | 2.96 - 3.19 |
| 52 week | 0.87 - 3.65 |
| Open | 3.18 |
| Vol / Avg. | 1.52M/2,757.00 |
| Mkt cap | 397.96M |
| P/E | - |
| Div/yield | - |
| EPS | - |
| Shares | 132.65M |
| Beta | - |
| Inst. own | - |
Events
Aug 14, 2013
Q2 2013 Topotarget A/S Earnings Release
May 2, 2013
Q1 2013 Topotarget A/S Earnings Conference Call
May 2, 2013
Q1 2013 Topotarget A/S Earnings Release
Apr 10, 2013
Topotarget A/S Annual General Meeting
Mar 13, 2013
Full Year 2012 Topotarget A/S Earnings Conference Call
Mar 13, 2013
Full Year 2012 Topotarget A/S Earnings Release
Mar 5, 2013
Topotarget A/S Belinostat BELIEF Trial Exceeds Primary Endpoint with Encouraging Response Rate Conference Call
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | - | -3397.33% |
| Operating margin | - | -3349.06% |
| EBITD margin | - | -3238.54% |
| Return on average assets | - | - |
| Return on average equity | - | - |
| Employees | 25 | - |
| Carbon Disclosure Rating | - | - |
Address
Fruebjergvej 3
KOEBENHAVN, 2100
Denmark
+45-39-178392 (Phone)
+45-39-179492 (Fax)
KOEBENHAVN, 2100
Denmark
+45-39-178392 (Phone)
+45-39-179492 (Fax)
Website links
External links
Advertisement
Description
Topotarget A/S is a Denmark-based biopharmaceutical company focused on the field of oncology. The Company is engaged in the development of cancer therapies, focusing primarily on the development of its principal drug candidate, Belinostat. Belinostat can be used in combination with full doses of chemotherapy, and is in a pivotal trial within peripheral T-cell lymphoma (PTCL) and phase II in cancer of unknown primary (CUP). It works in partnerships with Spectrum Pharmaceuticals Inc., Multimeric Biotherapeutics Inc. and the National Cancer Institute. As of December 31, 2011, the Company had five wholly owned subsidiaries, namely Topotarget UK Limited, Topotarget Germany AG, Topotarget USA Inc., Topotarget Switzerland S.A. and Topotarget Netherlands B.V. As of December 31, 2011, the Company�s two largest shareholders were HealthCap funds (13.01%) and Avanza bank (6.35%).
Officers and directors
| Bo Jesper Hansen M.D., Ph.D. | Chairman of the Board | |
| Francois R. Martelet | Chief Executive Officer | |
| Anders Fink Vadsholt | Chief Financial Officer | |
| Elisabeth V. Carstensen | Director of Pharmaceutical Operations | |
| Inge Holm Lauritzen | Vice President - Business Development & Licensing/Strategic Planning | |
| Annette Lykke | Director of Investor and Public Relations | |
| Axel Mescheder | Chief Medical Officer | |
| Per Samuelsson | Director | |
| Jeffrey H. Buchalter | Independent Director | |
| Anker Lundemose | Independent Director |